▼ -40.48% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for Isoray in the last 3 months. The average price target is $1.33, with a high forecast of $1.75 and a low forecast of $1.00. The average price target represents a -40.48% upside from the last price of $2.24.
The current consensus among 4 polled investment analysts is to buy stock in Isoray. This rating has held steady since October 2019, when it changed from a Hold consensus rating.
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray, Inc. was founded in 1998 and is headquartered in Richland, Washington.